Recruiting Multiple Myeloma Studies in Paris
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the contr...
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researche...
About Multiple Myeloma Clinical Trials in Paris
Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.
There are currently 2 multiple myeloma clinical trials recruiting participants in Paris, PARIS. These studies are seeking a combined 308 participants. Research is being sponsored by Sanofi, Glycomine, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Multiple Myeloma Clinical Trials in Paris — FAQ
Are there multiple myeloma clinical trials in Paris?
Yes, there are 2 multiple myeloma clinical trials currently recruiting in Paris, PARIS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Paris?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Paris research site will contact you about next steps.
Are clinical trials in Paris free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Paris studies also compensate for your time and travel.
What multiple myeloma treatments are being tested?
The 2 active trials in Paris are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.
Data updated March 2, 2026 from ClinicalTrials.gov